The current available treatments for PTSD are not fully effective for cognitive symptoms of
PTSD and have high drop-out and poor engagement, two factors found to be most indicative of
overall return to functioning for patients with PTSD. The proposed study directly addresses
this knowledge gap by conducting a pilot, fixed-dose, randomized, double-blind,
placebo-controlled, and cross-over trial using atomoxetine (ATX) as an add-on medication to
other therapies to testing the efficacy of ATX in reducing ADHD cognitive symptoms among
veterans with comorbid ADHD/PTSD. Successful completion of this pilot clinical trial may
build a platform for future large scale double-blind, placebo-controlled studies using either
atomoxetine or other cognitive enhancing medications.